Cr. Simith et al., Brief cyclosporine treatment prevents intrathymic (IT) tolerance inductionand precipitates acute rejection in an IT rat cardiac allograft model, TRANSPLANT, 69(2), 2000, pp. 294-299
Background. Intrathymic (IT) alloantigen combined with administration of ra
bbit anti-rat anti-lymphocyte serum (ALS) intraperitoneally induces donor-s
pecific tolerance to rat cardiac transplants. The purpose of this study was
to examine the effect of a brief course (4 days) of cyclosporine (CsA) on
the development of IT tolerance.
Methods. Buffalo (BUF) (RT1(b)) rats were given 25x10(6) fully MHC-mismatch
ed Lewis (LEW) (RT1(1)) splenocytes by IT injection plus 1.0 mi of ALS intr
aperitoneally. Twenty-one days later, IT donor-specific LEW (group 1) or th
ird-party (ACI, RT1(a)) (group 2) hearts were heterotopically transplanted
to the abdominal aorta. A third group of BUF (group 3) were given daily CsA
(10 mg/kg) by oral gavage for 4 days before administration of IT LEW cells
and ALS. Rejection as defined by the cessation of a palpable heartbeat was
confirmed by histology. Cytokine profiles of allografts from all groups we
re then analyzed using a multi-probe RNase protection assay.
Results. Sixty-seven percent of IT/ALS-treated BUF recipients not pretreate
d with CsA accepted LEW heart grafts for greater than 90 days. However, 86%
of animals treated with CsA for 4 days before IT injection and ALS rejecte
d allografts at 10.7+/-3.2 days. Third-party allografts (ACI) were uniforml
y rejected (7.0+/-0.0 days), Histology confirmed cellular rejection in CsA-
treated allografts and cytokine analysis detected increased interleukin (IL
)-3, IL-5, and tumor necrosis factor-or when compared to increased IL-2 and
interferon-gamma in rejecting untreated controls.
Conclusions. CsA can prevent the induction of intrathymic alloantigen toler
ance. These results support the development of a CsA-sensitive, but IL-a-in
dependent, active regulatory mechanism after intrathymic exposure to donor-
specific alloantigen and depletion of mature peripheral T cells.